02496 友芝友生物－Ｂ
YZYBIO-B
YZYBIO-B
| Listing Date | 2023/09/25 |
| Listing Price | 16.000 |
Quote
Subscription Result
- Subscription Rate13.81x
- Guarantee One Lot Size30 lot
- One Lot Success Rate18%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Wuhan YZY Biopharma Co. is a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and agerelated ophthalmologic diseases.
--
The Group have designed and developed a pipeline of seven clinical-stage drug candidates, including its Core Product M701, which it is currently conducting a Phase II clinical trial in treating malignant ascites (MA) and a Phase Ib/II clinical trial in treating malignant pleural effusion (MPE), and six other drug candidates at various clinical stages.
--
The Group is currently developing M701 primarily as a palliative care for MA and MPE, which are severe complications of cancer where fluids build up in the abdominal or chest cavity of cancer patients, and not for the treatment for cancer itself.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 11.00M H shares |
| No. of International Offer Shares | 9.90M H shares |
| No. of HK Offer Shares | 1.10M H shares |
| Offer Price | $16.00 - $20.00 |
| Stock Code | 2496 |
| Sponsor(s) | China Securities (International) Corporate Finance Company Limited |
| Underwriter(s) | China Securities (International) Corporate Finance Company Limited, Guotai Junan Securities (Hong Kong) Limited, CCB International Capital Limited, BOCI Asia Limited, TFI Securities and Futures Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Livermore Holdings Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Sep 13 (Wed) - noon, Sep 18 (Mon) |
| Price Determination Date | Sep 18 (Mon) |
| Result Announcement Date | On or before Sep 22 (Fri) |
| Result Announcement Date | On or before Sep 22 (Fri) |
| Result Announcement Date | On or before Sep 22 (Fri) |
| Dealings in Shares commence on | Sep 25, 2023. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $16.00 - $20.00 |
| Capitalization | 3.09B - 3.86B |
| NAV / share ($) | $1.23 - $1.45 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 18.00, the net proceeds raised would be HKD 142.40M, of which |
| 80% : For planned clinical trials, preparation for registration filings, and planned commercial launch of Core Product M701 |
| 12% : For planned clinical trials of Y101D |
| 8% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).